CANDEL THERAPEUTICS, INC. Depreciation
CANDEL THERAPEUTICS, INC. (CADL) reported Depreciation of $200.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. depreciation for the quarter ending 2026-06-30 was $200.00K, a 0.00% change year-over-year.
- CANDEL THERAPEUTICS, INC. depreciation for the quarter ending 2026-03-31 was $149.00K, a 39.18% decline year-over-year.
- CANDEL THERAPEUTICS, INC. depreciation for the quarter ending 2025-12-31 was $163.00K, a 33.47% decline year-over-year.
- CANDEL THERAPEUTICS, INC. depreciation for the quarter ending 2025-09-30 was $200.00K, a 0.00% change year-over-year.
- CANDEL THERAPEUTICS, INC. depreciation for fiscal 2025 was $845.00K, a 14.65% decline from fiscal 2024.
- CANDEL THERAPEUTICS, INC. depreciation for fiscal 2024 was $990.00K, a 3.13% increase from fiscal 2023.
- CANDEL THERAPEUTICS, INC. depreciation for fiscal 2023 was $960.00K, a 23.39% increase from fiscal 2022.
- CANDEL THERAPEUTICS, INC. depreciation for fiscal 2022 was $778.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-13 | $320.00K 10-Q · filed 2026-08-13 | $512.00K derived: sum of 3 quarters · filed 2026-08-13 | $712.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $149.00K 10-Q · filed 2026-05-14 | $312.00K derived: sum of 2 quarters · filed 2026-05-14 | $512.00K derived: sum of 3 quarters · filed 2026-05-14 | $712.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $363.00K derived: sum of 2 quarters · filed 2026-03-12 | $563.00K derived: sum of 3 quarters · filed 2026-08-13 | $845.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $200.00K 10-Q · filed 2025-11-13 | $400.00K derived: sum of 2 quarters · filed 2026-08-13 | $682.00K 10-Q · filed 2025-11-13 | $890.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $200.00K 10-Q · filed 2026-08-13 | $487.00K 10-Q · filed 2026-08-13 | $690.00K derived: sum of 3 quarters · filed 2026-08-13 | $890.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $245.00K 10-Q · filed 2026-05-14 | $490.00K derived: sum of 2 quarters · filed 2026-05-14 | $690.00K derived: sum of 3 quarters · filed 2026-05-14 | $890.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $245.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $445.00K derived: sum of 2 quarters · filed 2026-03-12 | $645.00K derived: sum of 3 quarters · filed 2026-03-12 | $990.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $200.00K 10-Q · filed 2025-11-13 | $400.00K derived: sum of 2 quarters · filed 2025-11-13 | $745.00K 10-Q · filed 2025-11-13 | $900.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $200.00K 10-Q · filed 2025-08-14 | $500.00K 10-Q · filed 2025-08-14 | $700.00K derived: sum of 3 quarters · filed 2025-08-14 | $900.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $251.00K 10-Q · filed 2025-05-13 | $500.00K derived: sum of 2 quarters · filed 2025-05-13 | $700.00K derived: sum of 3 quarters · filed 2025-05-13 | $900.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $449.00K derived: sum of 2 quarters · filed 2025-03-13 | $649.00K derived: sum of 3 quarters · filed 2025-03-13 | $960.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $200.00K 10-Q · filed 2024-11-14 | $400.00K derived: sum of 2 quarters · filed 2024-11-14 | $711.00K 10-Q · filed 2024-11-14 | $851.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $200.00K 10-Q · filed 2024-08-13 | $466.00K 10-Q · filed 2024-08-13 | $651.00K derived: sum of 3 quarters · filed 2024-08-13 | |
| 2023-03-31 | $230.00K 10-Q · filed 2024-05-14 | $451.00K derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $221.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $778.00K 10-K · filed 2024-03-28 | ||
| 2022-09-30 | $557.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |